The Federal Trade Commission (FTC) recently unanimously voted to withdraw its previously issued policy statement that opposed state legislation increasing transparency over pharmacy benefit managers (PBMs). Consistent with heightened scrutiny of PBMs by federal agencies, the FTC issued a statement cautioning against reliance on prior advocacy statements regarding PBMs that no longer may be valid.
The FTC stated that although prior advocacy statements undoubtedly were well-intentioned based on potential risks that existed at the time, the market has changed substantially since that time. As a result, increased transparency concerning PBMs is now preferable and even necessary instead of being seen as a risk to market competitiveness.
In June 2022, the FTC launched an inquiry into the country’s six largest PBMs to determine whether they engage in anticompetitive practices and restrict patient access to affordable medications. The three largest PBMs – CVS Caremark, Cigna’s Express Scripts, and UnitedHealth Group’s OptumRx – control almost 80% of the PBM market. The next three largest PBMs are Humana, Prime Therapeutics, and MedImpact Healthcare Systems.
The Pharmaceutical Care Management Association, representing the interests of the PBM industry, opposed the FTC’s decision and statement. The Association claims that although the market may have changed over the years, the PBM industry has only become more competitive, with 73 full-service PBMs operating nationwide.
HBL has experience in all areas of benefits and employment law, offering a comprehensive solution to all your business benefits and HR/employment needs. We help ensure you are in compliance with the complex requirements of ERISA and the IRS code, as well as those laws that impact you and your employees. Together, we reduce your exposure to potential legal or financial penalties. Learn more by calling 470-571-1007.
Hall Benefits Law, LLC
Latest posts by Hall Benefits Law, LLC (see all)
- Fifth Circuit Considers Arbitration Clause in ERISA Claim - March 20, 2026
